Pharmaceutical co-crystals - An opportunity for drug product enhancement

Expert Opinion on Drug Delivery

Volumn 6, Issue 4, 2009, Pages 333-341

  Miroshnyk, Inna ^a   Mirza, Sabiruddin ^a   Sandler, Niklas ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Co crystal formers; Co crystals; Crystal engineering; Solid state characterization; Supramolecular chemistry

Indexed keywords

ALCOHOL; AMIDE; BENZOIC ACID; CAFFEINE; CARBAMAZEPINE; CARBOXYLIC ACID; CRYSTALLIN; DRUG ADDITIVE; FLUOXETINE; FUMARIC ACID; GLUTARIC ACID; IBUPROFEN; INDOMETACIN; ISONICOTINAMIDE; ITRACONAZOLE; MALEIC ACID; MALIC ACID; MALONIC ACID; NICOTINAMIDE; NORFLOXACIN; OXALIC ACID; PHARMACEUTICAL CO CRYSTAL; SACCHARIN; SOLVENT; SUCCINIC ACID; TARTARIC ACID; UNCLASSIFIED DRUG;

BIOMEDICAL ENGINEERING; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR STABILITY; NEAR INFRARED SPECTROSCOPY; REVIEW; SOLID STATE; SUPRAMOLECULAR CHEMISTRY; X RAY DIFFRACTION;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG STABILITY; EXCIPIENTS; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 67649134796     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902828304     Document Type: Review

References (60)

1. Almarsson O, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem Commun 2004;17:1889-1896
2. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007;59:617-630 (Pubitemid 47285407)
3. Issa N, Karamertzanis PG, Welch GWA, Price SL. Can the formation of pharmaceutical cocrystals be computationally predicted? I. Comparison of lattice energies. Cryst Growth Des 2009;9:442-453
4. Vogt FG, Clawson JS, Strohmeier M, et al. Solid-state NMR analysis of organic cocrystals and complexes. Cryst Growth Des 2009;9:921-937
5. Reddy LS, Bethune SJ, Kampf JW, Rodriguez-Hornedo N. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst Growth Des 2008;9:378-385
6. Schartman RR. On the thermodynamics of cocrystal formation. Int J Pharm 2009;365:77-80
7. Velaga SP, Basavoju S, Bostroem D. Norfloxacin saccharinate-saccharin dihydrate cocrystal - a new pharmaceutical cocrystal with an organic counter ion. J Mol Struct 2008;889:150-153
8. Cooke CL, Davey RJ. On the solubility of saccharinate salts and cocrystals. Cryst Growth Des 2008;8:3483-3485
9. He G, Jacob C, Guo L, et al. Screening for cocrystallization tendency: the role of intermolecular interactions. J Phys Chem B 2008;112:9890-9895
10. Childs SL, Rodriguez-Hornedo N, Reddy LS, et al. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. Cryst Eng Comm 2008;10:856-864
11. Takata N, Shiraki K, Takanao R, et al. Cocrystal screening of stanolone and mestanolone using slurry crystallization. Cryst Growth Des 2008;8:3032-3037
12. Berry DJ, Seaton CC, Clegg W, et al. applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients. Cryst Growth Des 2008;8:1697-1712
13. Sun CC, Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Cryst Growth Des 2008;8:1575-1579
14. Basavoju S, Boström D, Velaga SP. Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm Res 2008;25:530-541 (Pubitemid 351357724)
15. Porter WW, Elie SC, Matzger AJ. Polymorphism in carbamazepine cocrystals. Cryst Growth Des 2008;8:14-16
16. Rodriguez-Hornedo N. Cocrystals: molecular design of pharmaceutical materials. Mol Pharm 2007;4:299-300 (Pubitemid 46983945)
17. Babu NJ, Reddy LS, Nangia A. Amide-N-oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine N-oxides. Mol Pharm 2007;4:417-434 (Pubitemid 46983957)
18. Stahly GP. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst Growth Des 2007;7:1007-1026
19. Remenar JF, Peterson ML, Stephens PW, et al. Celecoxib: nicotinamide dissociation: using excipients to capture the Cocrystal;s potential. Mol Pharm 2007;4:386-400 (Pubitemid 46983955)
20. Karki S, Friscic T, Jones W, Motherwell WDS. Screening for pharmaceutical cocrystal hydrates via neat and liquid-assisted grinding. Mol Pharm 2007;4:347-354 (Pubitemid 46983951)
21. Nguyen KL, Friscic T, Day GM, et al. Terahertz time-domain spectroscopy and the quantitative monitoring of mechanochemical cocrystal formation. Nat Mater 2007;6:206-209 (Pubitemid 46353768)
22. Hickey MB, Peterson ML, Scoppettuolo LA, et al. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm 2007;67:112-119 (Pubitemid 46991320)
23. Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov 2004;3:42-57 (Pubitemid 38088697)
24. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. Pharmaceutical co-crystals. J Pharm Sci 2006;95:499-516
25. Desiraju GR. Supramolecular synthons in crystal engineering - a new organic synthesis. Angew Chem Int Ed Engl 1995;34:2311-2327
26. Fleischman SG, Kuduva SS, McMahon JA, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst Grow Des 2003;3:909-919 (Pubitemid 37474229)
27. Aakeröy CB, Salmon DJ. Building cocrystals with molecular sense and supramolecular sensibility. Cryst Eng Commun 2005;7:439-448 (Pubitemid 41396867)
28. Braga D, Grepioni F. Making crystals from crystals: a green route to crystal engineering and polymorphism. Chem Commun 2005;4(3):3635-3645 (Pubitemid 41133134)
29. Bis JA, Vishweshwar P, Weyna D, et al. Hierarchy of supramolecular synthons: persistent hydroxyl-pyridine hydrogen bonds in cocrystals that contain a cyano acceptor. Mol Pharm 2007;4(3):401-416 (Pubitemid 46983956)
30. Bettinetti G, Caira MR, Callegari A, et al. Structure and solid-state chemistry of anhydrous and hydrated crystal forms of the trimethoprim- sulfamethoxypyridazine 1:1 molecular complex. J Pharm Sci 2000;89:478-489 (Pubitemid 30696717)
31. Caira MR. Sulfa drugs as model cocrystal formers. Mol Pharm 2007;4:310-316 (Pubitemid 46983947)
32. Aakeröy CB, Fasulo ME, Desper J. Cocrystal or salt: does it really matter? Mol Pharm 2007;4:317-322
33. Remenar JF, Morissette SL, Peterson ML, et al. Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125:8456-8457 (Pubitemid 36858412)
34. Desiraju GR. Crystal Engineering. The Design of Organic Solids, Materials Science. Amsterdam, The Netherlands: Elsevier, 1989
35. Top 300 prescriptions for 2005 by number of US prescriptions dispensed. San Clemente, CA: RxList. Available from: http://www.rxlist.com/top200.htm [Last accessed 17 Feb 2009]
36. Zhang GG, Henry RF, Borchardt TB, Lou X. Efficient co-crystal screening using solution-mediated phase transformation. J Pharm Sci 2007;96:990-995 (Pubitemid 46797470)
37. Trask AV, Jones W. Crystal engineering of organic co-crystals by the solid-state grinding approach. Top Curr Chem 2005;254:41-70 (Pubitemid 44420828)
38. Blagden N, Berry DJ, Parkin A, et al. Current directions in co-crystal growth. N J Chem 2008;32:1659-1672
39. Childs SL, Rodriguez-Hornedo N, Reddy LS, et al. Screening strategies based on solubility and solution composition generate pharmaceutcailssy acceptable cocrytsls of carbamazepine. Cryst Eng Commun 2008;10:856-864
40. Etter MC, Reutzel SM, Choo CG. Selforganization of adenine and thymine in the solid state. J Am Chem Soc 1993;115:4411-4412
41. Caira MR, Nassimbeni LR, Wildervanck AF. Selective formation of hydrogen bonded co-crystals between a sulfonamide and aromatic carboxylic acids in the solid state. J Chem Soc Perkin Trans 1995;2:2213-2216
42. Kuroda R, Imai Y, Tajima N. Generation of a co-crystal phase with novel coloristic properties via solid state grinding procedures. Chem Commun 2002;2848-2849 (Pubitemid 35375711)
43. Trask AV, Motherwell WDS, Jones W. Solvent-drop grinding: green polymorph control of co-crystallisation. Chem Commun 2004;890-891 (Pubitemid 38530287)
44. Oberoi LM, Alexander KS, Riga AT. Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients. J Pharm Sci 2005;94:93-101 (Pubitemid 40116373)
45. Trask AV, Motherwell WDS, Jones W. Pharmaceutical co-crystallization: engineering a remedy for caffeine hydration. Cryst Grow Des 2005:5:1013-1021 (Pubitemid 40755572)
46. Childs SL, Hardcastle KI. Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des 2007;7:1291-1304
47. Miroshnyk I, Khriachtchev L, Mirza S, et al. Insight into thermally induced phase transformations of erythromycin A dihydrate. Cryst Growth Des 2006;6:369-374 (Pubitemid 43242095)
48. Basavoju S, Boström D, Velaga SP. Pharmaceutical cocrystal and salts of norfloxacin. Cryst Growth Des 2006;6:2699-2708
49. Allesø M, Velaga S, Alhalaweh A. Near-infrared spectroscopy for cocrystal screening. A comparative study with raman spectroscopy. Anal Chem 2008;80:7755-7764
50. Gardner CR, Walsh CT, Almarsson O. Drugs as materials: valuing physical form in drug discovery. Nat Rev Drug Discov 2004;3:926-934 (Pubitemid 39529930)
51. Khankari RK, Grant DJW. Pharmaceutical hydrates. Thermochim Acta 1995;248:61-79
52. Byrn SR, Pfeiffer RR, Stowell JG. Solid-State Chemistry of Drugs. Second edition. West Lafayette, IN: SSCI, Inc., 1999
53. Airaksinen S, Karjalainen M, Kivikero N, et al. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation. AAPS PharmSciTech 2006;6:311-322 (Pubitemid 41631741)
54. Jørgensen A, Miroshnyk I, Karjalainen M, et al. Multivariate data analysis as a fast tool in evaluation of solid state phenomena. J Pharm Sci 2006;95:906-916
55. Mirza S, Miroshnyk I, Rantanen J, et al. Solid-state properties and relationship between anhydrate and monohydrate of baclofen. J Pharm Sci 2007;96:2399-2408 (Pubitemid 47477895)
56. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev 2001;48:91-114 (Pubitemid 32452293)
57. Sun CC, Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Crys Growth Des 2008;8:1575-1579
58. Childs SL, Chyall LJ, Dunlap JT, et al. Crystal engineering approach to forming co-crystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 2004;126:13335-13342 (Pubitemid 39382761)
59. Walsh RDB, Bradner MW, Fleischman S, et al. Crystal engineering of the composition of pharmaceutical phases. Chem Commun 2003;2:186-187 (Pubitemid 36138703)
60. Trask AV. An overview of pharmaceutical cocrystals as intellectual property. Mol Pharm 2007;4:301-330 (Pubitemid 46983946)